Supply of salpraz heartburn relief by Alphapharm Pty Limited

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, is designed to regulate therapeutic goods, including medicines, to ensure they are of acceptable quality, safety, and efficacy. A gap in compliance was identified with respect to the labelling standards for medicines, specifically concerning batch numbers and expiry dates, which are crucial for consumer safety and regulatory oversight. This legislative framework provides the necessary authority to the Department of Health and Ageing to grant consents that allow for certain deviations from the prescribed labelling standards under strict conditions. The policy objective underpinning this Act is to safeguard public health by ensuring that therapeutic goods meet essential quality and safety standards while maintaining flexibility where necessary to address legitimate operational needs. The notice issued under section 14A of the Act by Mayada Kayali, a delegate of the Secretary, illustrates the application of this legislative intent, allowing Alphapharm Pty Limited to supply two specific batches of SALPRAZ HEARTBURN RELIEF that do not fully comply with the labelling standards, provided all other aspects of the standard are met. This measure exemplifies the Act's role in balancing regulatory rigour with practical considerations in the pharmaceutical supply chain.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods in Australia, encompassing a wide range of products including medicines, medical devices, blood, and tissues. The Act applies to various entities such as manufacturers, importers, suppliers, and advertisers of therapeutic goods, and it sets out the legal framework for the authorisation, supply, and advertising of these goods. The Act’s jurisdiction is national, as it is a Commonwealth Act and applies across Australia, ensuring a uniform regulatory approach to therapeutic goods. Section 14 of the Act allows for specific consents to be granted in certain circumstances, such as deviations from labelling standards, subject to conditions to ensure consumer safety and product efficacy. In the given notice, the delegate of the Secretary has granted consent for Alphapharm Pty Limited to supply two batches of SALPRAZ HEARTBURN RELIEF that do not fully comply with the Therapeutic Goods Order No. 69, specifically regarding the inclusion of required prefixes for the batch number and expiry date on the packaging. However, this consent is conditional upon the product adhering to all other aspects of the standard, thereby maintaining the overarching safety and quality controls prescribed by the Act.

Key Provisions

The main operative sections of this legislation are sections 14, 14A, and 15 of the Therapeutic Goods Act 1989 (the Act). Section 14 allows for the delegate of the Secretary to the Department of Health and Ageing to give consent for the supply of therapeutic goods that do not comply with certain regulations, in this case, Therapeutic Goods Order No. 69 – General Requirements for Labelling for Medicines. This consent is subject to specific conditions, as outlined in section 15(1). In this instance, the delegate has given consent for Alphapharm Pty Limited to supply two specific batches of SALPRAZ HEARTBURN RELIEF pantoprazole (as sodium sesquihydrate) 20 mg enteric coated tablet blister packs (AUST R 169504) that do not include the required prefixes for the batch number and expiry date, provided that the product complies with all other aspects of the standard. The Act imposes specific obligations on the parties it governs. For Alphapharm Pty Limited, the primary obligation is to ensure that the supplied product meets all requirements stipulated in the Therapeutic Goods Order No. 69, except for the omission of the required prefixes for the batch number and expiry date, which has been specifically exempted by the delegate’s consent. The company must adhere to all other labelling standards and ensure that the product is safe and of high quality for consumer use. Additionally, the delegate of the Secretary is required to carefully consider the conditions under which such consent is granted, ensuring that the exemption does not compromise the safety or efficacy of the therapeutic goods. There are potential civil and criminal consequences for breaches of this legislation. The Therapeutic Goods Act 1989 provides for various offences that can be incurred if the requirements of the Act or the Therapeutic Goods Order are breached. These may include supplying therapeutic goods that do not comply with the labelling requirements, which can result in significant fines and penalties. For example, under section 33DA of the Act, the maximum penalty for contravening labelling requirements can be substantial, potentially amounting to thousands of dollars, depending on the severity and frequency of the breach. Additionally, criminal charges may be brought against individuals or companies found to be in serious or repeated breach of the Act, leading to potential imprisonment. In summary, the legislation allows for the supply of therapeutic goods that do not meet certain labelling requirements, subject to specific conditions. The obligations on the parties governed by this Act include ensuring compliance with all labelling standards except for the exempted prefix requirement, and the delegate’s responsibility to grant consent under appropriate conditions. The potential consequences for breaches include significant financial penalties and, in severe cases, criminal charges. It is crucial for parties involved to adhere to the provisions of the Act to avoid these serious repercussions.